Abstract-Angiotensin II (Ang II), an effector peptide of the renin-angiotensin system, has been reported to stimulate growth of blood vessels in vivo and smooth muscle cells in culture. In this study, the effect of Ang II on DNA synthesis was examined in deendothelialized human saphenous vein in organ culture. After 7 days' exposure to medium containing 0.4% fetal calf serum plus Ang II, there was a marked increase in DNA synthesis. The effect of Ang II was comparable to the response to platelet-derived growth factor. Responses to Ang II were partially inhibited by the AT 1 receptor antagonist candesartan. An AT 2 receptor antagonist, PD123319, had no effect on Ang II-induced DNA synthesis, either alone or in combination with candesartan. and inhibits neointimal growth after vascular injury in rats. 6 However, such effects may be species dependent, because ACEI has been reported to have little or no effect on the response to vascular injury in rabbits, 7 pigs, 8 or baboons. 9 In addition, an ACEI also failed to reduce the incidence of restenosis in a recent clinical trial.
A ngiotensin II (Ang II) is an important regulator of vascular smooth muscle cell growth: infusion of Ang II stimulates vascular hypertrophy in rats, [1] [2] [3] independently of changes in blood pressure, 1, 3 and also enhances neointimal formation after vascular injury. 4 Inhibition of Ang II formation by angiotensin-converting enzyme inhibitors (ACEI) reverses vascular hypertrophy associated with hypertension 5 and inhibits neointimal growth after vascular injury in rats. 6 However, such effects may be species dependent, because ACEI has been reported to have little or no effect on the response to vascular injury in rabbits, 7 pigs, 8 or baboons. 9 In addition, an ACEI also failed to reduce the incidence of restenosis in a recent clinical trial. 10 Angiotensin type 1 (AT 1 ) receptors are considered to mediate most of the effects of Ang II on vascular growth, 11 although angiotensin type 2 (AT 2 ) receptors may also contribute. [12] [13] [14] Rodent vascular injury models have been reported to overexpress AT 1 receptors, 15 and an AT 1 antagonist inhibits neointimal hyperplasia in injured rat carotid arteries. 16 In contrast, an AT 1 antagonist had no effect on intimal hyperplasia in a porcine vascular injury model. 17 Ang II has also been reported to promote the growth of cultured smooth muscle cells. Ang II stimulated 3 H-thymidine and 3 H-leucine incorporation in smooth muscle cells derived from human aorta and subcutaneous arteries. 18 In contrast, in human coronary smooth muscle cells, Ang II stimulated protein synthesis but not DNA synthesis. 19 In human saphenous vein-derived smooth muscle cells, Ang II induced some DNA synthesis in one study 20 but failed to stimulate proliferation or protein synthesis in another. 21 Although these data provide some evidence for trophic effects of Ang II, isolated cells may lack cell-cell and cell-matrix interactions that influence responses to growth factors. We therefore examined the effect of Ang II on DNA synthesis in human saphenous vein segments in an organ culture system in which such interactions are maintained. These studies also examined the involvements of receptor subtypes and the possible role of tyrosine kinase activation in Ang II-induced responses.
Methods

Clinical Details
Segments of veins surplus to clinical requirement were obtained from 55 patients (43 men and 12 women, age range 50 to 78 years) who were undergoing coronary artery bypass surgery. Studies were in accordance with local ethics committee guidelines. Patients taking ACEI or AT 1 antagonists before surgery were excluded from the study.
Tissue Preparation and Culture
Segments of vein were transferred to the tissue culture laboratory in cold Hanks' balanced sale solution buffered with 25 mmol/L HEPES and prepared for culture by a procedure based on that described by Soyombo et al. 22 Briefly, the adventitia and extraneous adhering fat were removed, and the vein was cut open longitudinally. The luminal surface was gently rubbed with a sterile cotton bud to remove the endothelium, and the tissue was then cut into Ϸ5-mm segments. Segments were then pinned, luminal surface uppermost, onto culture dishes precoated with a layer of silicone elastomer. Culture dishes were filled with medium consisting of Dulbecco's modified Eagle medium (DMEM) supplemented with penicillin (100 U/mL), streptomycin (100 g/mL), and gentamicin (25 g/mL). Veins were cultured in a humidified atmosphere of 5% (vol/vol) carbon dioxide in air at 37°C for 7 days in DMEM containing 0.4% serum (SFM), 30% serum, or SFM plus drugs. Antagonists or peptide analogues were incubated with tissues for at least 10 minutes before the addition of Ang II. Drugs and peptides were replenished daily throughout the culture period.
Measurement of DNA Synthesis
DNA synthesis was determined by measuring the incorporation of 3 H-methylthymidine.
3 H-methylthymidine (1 Ci/mL) was added to the culture dishes for 24 hours, and the experiment was then terminated by washing the vein segments twice with ice-cold PBS. All studies were performed in triplicate. Tissue wet weight was recorded, and veins were then lysed by exposure to a tissue solubilizer (NCS-II; Amersham) for 48 hours. The acid insoluble fraction was then extracted on ice with 10% (wt/vol) trichloroacetic acid. Radioactivity was determined by means of a scintillation counter, and the counts per minute (cpm) were normalized to micrograms of wet tissue weight. Initial experiments were performed to determine a time course for 3 H-thymidine incorporation into human saphenous vein in organ culture. Veins were incubated in culture medium containing 0.4%, 1%, or 30% serum for 3 time points: 1 day, 3 days, and 7 days. At the end of these time points, 3 H-thymidine incorporation was maximal in response to 30% serum after 7 days (Ϸ10-fold increase), and therefore this time point was chosen for all subsequent experiments.
Morphometric Analysis
After culture, vein segments from some treatment groups were fixed in 10% formalin, embedded in paraffin, and stained with Miller's elastic and van Giessen stains. Randomly selected vein sections were also stained with hematoxylin-eosin or immunostained with a monoclonal Ki67 (Novacastra) antibody (counterstained with hematoxylin) to identify the nuclear antigen (Ki67) associated with cell proliferation. For quantification of Ki67 labeling, total cell number and the number of Ki67-positive cells were counted in the media of vein sections using a ϫ40 objective. Vein wall thickness was determined by morphometric analysis of images generated by a Zeiss Axioscope equipped with a CCD camera and appropriate software (NIH Image). Intimal/neointimal thickness was defined by tissue on the luminal side of the internal elastic lamina (a trace of acellular thickening was present in this layer of all vein segments before culture). Medial thickness was defined by tissue enclosed by the internal and external elastic laminae.
Drugs
Candesartan and EXP3174 were gifts from Takeda Inc and DuPont, respectively. Ang II is rapidly broken down by tissue proteases and therefore is able to achieve stable levels in culture. Ang II (1 to 100 nmol/L) was delivered via osmotic minipumps (Charles River) at an infusion rate of 0.5 L/h. This method of administration resulted in concentrations of Ang II in culture medium of 8.5Ϯ0.7ϫ10 -8 mol/L as measured by radioimmunoassay on day 7 using Ang II (100 nmol/L). Candesartan stock was made up in dimethyl sulfoxide (DMSO); the final concentration of DMSO did not exceed 0.0001%. Other antagonists and peptides were made up in PBS.
Statistical Analysis
Treatment groups were compared by Student's paired and unpaired t test as appropriate or repeated-measures ANOVA for comparison of 3 or more groups, followed by Dunnett's test with Instat 3.02 (GraphPad Software Inc). Statistical significance was accepted at PϽ0.05. All values are meanϮSEM of n observations.
Results
Ang II (1 to 100 nmol/L) caused a marked, concentrationdependent increase in DNA synthesis over 7 days ( Figure  1A ). Tyrphostin-23, a selective inhibitor of tyrosine kinases, reduced 3 H-thymidine incorporation in SFM and also abolished the increase induced by Ang II (10 nmol/L). Responses to Ang II varied between individuals, but overall Ang II (10 nmol/L) significantly increased DNA synthesis compared with veins exposed to SFM ( Figure 1B ). Responses to Ang II were comparable in magnitude to those to platelet-derived growth factor-AB (PDGF-AB; 1 ng/mL), although less than those to 30% serum ( Figure 1B) .
We examined the role of AT 1 receptors in responses to Ang II by incubating veins with Ang II and the nonpeptide AT 1 antagonist candesartan. Candesartan (1 nmol/L) had no significant effect on DNA synthesis in SFM or 30% serum (data not shown), but it significantly attenuated responses to Ang II (10 nmol/L) (Figure 2A ). Higher concentrations of candesar- tan had no additional effect, and the active metabolite of the related AT 1 receptor antagonist, losartan (EXP3174; 10 mol/L), caused responses to Ang II to be diminished to a similar extent (Ang IIϩEXP3174ϭ57Ϯ47% of Ang II response; nϭ3). The selective AT 2 receptor antagonist PD123319 (100 nmol/L) had no significant effect on the Ang II response (Figure 2A ). The combination of PD123319 (100 nmol/L) and candesartan (10 nmol/L) also did not inhibit responses to Ang II to a greater extent than candesartan alone.
In Figure 2B ). In the presence of saralasin (1 mol/L), DNA synthesis in response to Ang II was abolished ( Figure 2B ).
In addition to stimulation of DNA synthesis, Ang II caused a small and statistically insignificant increase in thickness of the vein media by 28Ϯ17% (nϭ7). There was no significant change in intimal thickness. Endothelial cell regeneration did not occur over the course of the study, as indicated by the lack of immunohistochemical staining for the endothelial cell antigen CD31 (data not shown). Ang II caused a significant increase in the percentage of Ki67-positive cells (taken as an index of proliferating cells) in the media of vein sections (SFMϭ2.2Ϯ1%; Ang IIϭ6.2Ϯ0.7%; nϭ3; PϽ0.01). After hematoxylin-eosin staining of vein sections, medial nuclear density appeared to be increased by 30% serum and Ang II. Ang II and 30% serum did not induce detectable differences in histological appearance after Miller's elastin or van Giessen staining.
Discussion
Organ culture studies may have advantages over those that use isolated cells, because cell-cell and cell-extracellular matrix interactions are preserved, and these may influence growth factor responses. 23 In our studies, Ang II caused a marked concentration-dependent increase in DNA synthesis in veins cultured for 7 days in medium containing minimal (0.4%) serum. The responses to Ang II in this model were of comparable magnitude to those of a classic mitogen, PDGF. This finding contrasts with the modest stimulation of 3 Hthymidine incorporation seen in an earlier study of isolated smooth muscle cells cultured from human saphenous vein. 20 Further studies indicated that exposure to Ang II was also accompanied by Ϸ3-fold increase in proliferating cell nuclear antigen Ki67-positive cells in vein media, providing further evidence for hyperplasia in response to Ang II. The failure to observe a significant increase in neointima in response to Ang II in these preparations is likely to be due to the removal of the endothelium, because this has been reported to inhibit spontaneous neointima formation in this preparation. 22 The extent of DNA synthesis seen in response to Ang II varied between individuals. The reasons for this are not known, but it perhaps should not be unexpected given the diversity of patient ages and conditions. Interindividual differences in the rate of growth and sensitivity to growth inhibitors have also been observed in vascular smooth muscle cells cultured from saphenous vein taken from different individuals. 24 The effect of Ang II on DNA synthesis in our vascular model is in contrast with 2 recent studies in which Ang II did not influence DNA synthesis over 3 days of incubation with rat aorta 25 and renal artery 26 segments in organ culture. In those studies, protein synthesis 25 and medial hypertrophy 26 were induced. Aside from interspecies differences, several possibilities may explain the difference between the present and former studies. First, in the previous investigations, daily replenishment of Ang II was used. The biological half-life of Ang II in culture systems is extremely short, because it is broken down by tissue proteases. 27 It is possible that the continuous exposure achieved in the present study with osmotic minipump infusions may better stimulate DNA synthesis. Second, the longer duration of stimulation with Ang II in the present study (7 days versus 3 days) may also be a contributory factor. Although Ang II can stimulate phospholipase C and generation of diacylglycerol and inositol 1,4,5-trisphosphate within seconds or minutes, tissue exposure to Ang II for Ͼ48 hours can activate a delayed stimulation of DNA synthesis through the autocrine or paracrine production of secondary growth factors. Activation of tyrosine kinases is believed to participate in multiple steps of signal transduction initiated by a variety of growth factors, including PDGF and, more recently, Ang II. 29 The effect of Ang II may involve direct effects on tyrosine kinases 29 or transactivation of growth factor receptors. 30 In the present study, Ang II-induced DNA synthesis was totally abolished by the tyrosine kinase inhibitor tyrphostin-23, implying a role for tyrosine kinases in the response to Ang II. Interestingly, 3 H-methylthymidine incorporation in 0.4% serum was also inhibited by tyrphostin-23, which suggests that some DNA synthesis may occur even in the absence of any growth factor, possibly as a result of injury during vein preparation. 22, 31 We are unaware of any previous reports concerning the identity of the angiotensin receptor subtype involved in Ang II-mediated growth in intact human vascular tissue in organ culture, although the trophic actions of Ang II on isolated smooth muscle cells derived from human and animal tissue are mediated by the AT 1 receptor subtype. 11, 15, 16, 32, 33 In our studies, the AT 1 receptor antagonists candesartan and EXP3174 only partially inhibited Ang II-induced DNA synthesis. The concentration of candesartan was chosen on the basis of previous functional studies showing that the estimated affinity (K B ) of candesartan for the AT 1 receptor in human arteries was Ϸ10 pmol/L. 34 In previous studies, similar (and lower) concentrations of these antagonists have been shown to completely inhibit DNA synthesis in rat aortic 32 and human aortic vascular smooth muscle cells in culture. 33 The inability of candesartan and losartan to completely inhibit responses to Ang II implies involvement of another receptor subtype. However, the AT 2 receptor antagonist PD123319, either alone or in combination with candesartan, had no effect on responses to Ang II. It is possible, therefore, that the effect of Ang II was mediated in part by a non-AT 1 /non-AT 2 receptor. Consequently, we examined the effects of the nonselective Ang II peptide antagonists saralasin and sarthran. In many preparations, these agents act as antagonists of angiotensin receptors 35, 36 and the receptor for angiotensin 1-7. 37 In our study, both saralasin and sarthran acted as agonists and increased DNA synthesis to levels comparable to Ang II itself. In the presence of saralasin, Ang II-induced DNA synthesis was abolished, which indicates that Ang II and the peptide antagonists act at common receptors. This effect of the peptide antagonists could involve the internalization or desensitization of receptors for Ang II. 38, 39 These observations appear consistent with an AT receptor of undefined subtype contributing to DNA synthesis in response to Ang II; however, additional studies, such as ligand binding studies with radiolabeled Ang II and AT 1 antagonists, would be valuable in confirming this possibility.
Non-AT 1 /non-AT 2 receptors have previously been described in tissues of avian species, [40] [41] [42] [43] and a unique Ang II binding site in human endometrium has also been described. 44 Interestingly, saralasin has been reported to be a partial agonist at the atypical AT receptor found in the nasal salt gland of Anas platyrhynchos. 40 A role for non-AT 1 /non-AT 2 receptors in cellular growth in humans has also been proposed. Recently, non-AT 1 /non-AT 2 receptors have been reported to mediate Ang II-induced growth in human cardiac fibroblasts 45 and human keratinocytes 46 in culture. Degradation products of the octapeptide Ang II (or its precursor molecules) may also exert actions on cells via non-AT 1 /non-AT 2 receptors. Thus, angiotensin (1-7) 37, 43 and angiotensin IV (3-8) 47, 48 have been reported to promote or inhibit DNA synthesis in a variety of cell types. It would be important to examine the effects of these analogues and their antagonists in this preparation in future studies.
In summary, the present study demonstrates that Ang II induces marked DNA synthesis in saphenous vein organ culture model via a mechanism that involves activation of tyrosine kinases. Ang II-induced DNA synthesis is mediated in part by AT 1 receptors, but it is likely that an atypical receptor (for which sarthran and sarile are agonists) may also contribute. Enhanced vascular smooth muscle cell growth is considered to have an important role in various pathophysiological processes, and consequently, defining the angiotensin receptor subtypes involved in this response may have important clinical implications.
